Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
Jingjing Li, Xuanfu Xu Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of ChinaCorrespondence: Xuanfu Xu, Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of China, Tel +86-021-25066666, Email shuanfusky@163.comAbstra...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-04-01
|
| Series: | International Journal of General Medicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/immune-checkpoint-inhibitor-based-combination-therapy-for-colorectal-c-peer-reviewed-fulltext-article-IJGM |
| _version_ | 1827958382520172544 |
|---|---|
| author | Li J Xu X |
| author_facet | Li J Xu X |
| author_sort | Li J |
| collection | DOAJ |
| description | Jingjing Li, Xuanfu Xu Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of ChinaCorrespondence: Xuanfu Xu, Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of China, Tel +86-021-25066666, Email shuanfusky@163.comAbstract: Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body’s autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.Keywords: immune checkpoint inhibitors, colorectal cancer, PD-1/PD-L1, combination therapy, DNA mismatch repair |
| first_indexed | 2024-04-09T15:35:52Z |
| format | Article |
| id | doaj.art-c25bd4c900d14d039c8f8ec2d48f4395 |
| institution | Directory Open Access Journal |
| issn | 1178-7074 |
| language | English |
| last_indexed | 2024-04-09T15:35:52Z |
| publishDate | 2023-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of General Medicine |
| spelling | doaj.art-c25bd4c900d14d039c8f8ec2d48f43952023-04-27T19:02:47ZengDove Medical PressInternational Journal of General Medicine1178-70742023-04-01Volume 161527154083318Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An OverviewLi JXu XJingjing Li, Xuanfu Xu Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of ChinaCorrespondence: Xuanfu Xu, Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, People’s Republic of China, Tel +86-021-25066666, Email shuanfusky@163.comAbstract: Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body’s autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.Keywords: immune checkpoint inhibitors, colorectal cancer, PD-1/PD-L1, combination therapy, DNA mismatch repairhttps://www.dovepress.com/immune-checkpoint-inhibitor-based-combination-therapy-for-colorectal-c-peer-reviewed-fulltext-article-IJGMimmune checkpoint inhibitorscolorectal cancerpd-1/pd-l1combination therapydna mismatch repair |
| spellingShingle | Li J Xu X Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview International Journal of General Medicine immune checkpoint inhibitors colorectal cancer pd-1/pd-l1 combination therapy dna mismatch repair |
| title | Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview |
| title_full | Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview |
| title_fullStr | Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview |
| title_full_unstemmed | Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview |
| title_short | Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview |
| title_sort | immune checkpoint inhibitor based combination therapy for colorectal cancer an overview |
| topic | immune checkpoint inhibitors colorectal cancer pd-1/pd-l1 combination therapy dna mismatch repair |
| url | https://www.dovepress.com/immune-checkpoint-inhibitor-based-combination-therapy-for-colorectal-c-peer-reviewed-fulltext-article-IJGM |
| work_keys_str_mv | AT lij immunecheckpointinhibitorbasedcombinationtherapyforcolorectalcanceranoverview AT xux immunecheckpointinhibitorbasedcombinationtherapyforcolorectalcanceranoverview |